Certara Inc. (CERT) has drawn attention in recent sessions following its third-quarter results and a series of product launches that highlight its focus on biosimulation and regulatory technology. With steady revenue growth and updated guidance, the company continues to position itself as a notable player in the life sciences technology space.
Recent Q3 Highlights
Earlier this month, Certara reported net income of $1.5 million for the third quarter of 2025, reversing a net loss of $1.4 million in the same period last year. Earnings per share came in at $0.01 compared to a loss of $(0.01) per share in 2024. Adjusted net income rose to $22.2 million from $20.3 million, while adjusted earnings per share remained steady at $0.14.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.